Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
Milan, Italy5 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease | Digestive System Diseases, Digestive System Neoplasms, Neoplasm, Residual, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, digestive system disorder, digestive system neoplasm, gastric cancer, gastric neoplasm, neoplasm, stomach disorder | Recruiting | Phase 2 | 2026-09-23 | NCT06253650 | |
| TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC. | Digestive System Diseases, Digestive System Neoplasms, Genomic Instability, Microsatellite Instability, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, digestive system disorder, digestive system neoplasm, gastric cancer, gastric neoplasm, neoplasm, stomach disorder | Active, not recruiting | Phase 2 | 2026-09-11 | NCT04817826 | |
| Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery | DNA Virus Infections, Infections, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Tumor Virus Infections, adenocarcinoma, carcinoma, cutaneous neuroendocrine carcinoma, epithelial neoplasm, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, polyomavirus infectious disease, primitive neuroectodermal tumor, viral infectious disease | Active, not recruiting | Phase 2 | 2026-01-14 | NCT05594290 | |
| Radiomics and Molecular Classification in Endometrial Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine cancer, uterine disorder | Active, not recruiting | Not applicable | 2025-05-09 | NCT06963385 | |
| Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, bladder transitional cell carcinoma, neoplasm, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Not yet recruiting | Phase 2 | 2024-07-30 | NCT06528483 |